Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
Design Therapeutics (Nasdaq: DSGN) will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.m. ET in New York.
A live webcast and 30-day archive will be available in the investors section of the company’s website.
Positive
- None.
Negative
- None.
News Market Reaction – DSGN
On the day this news was published, DSGN declined 3.24%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 18 | Clinical data update | Positive | -25.5% | Four-week RESTORE-FA DT-216P2 data showing clinical and biomarker improvements. |
| May 17 | Investor webcast | Neutral | -25.5% | Announcement of investor webcast to review RESTORE-FA trial data. |
| Apr 28 | Earnings and updates | Positive | +23.3% | Q1 2026 results with $222.8M cash and multiple clinical readouts expected. |
| Mar 9 | Earnings and updates | Neutral | -3.7% | FY 2025 results and progress across three GeneTAC clinical programs. |
| Feb 18 | Investor conferences | Neutral | -0.9% | Participation in Oppenheimer and Leerink investor conferences with webcast access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows strong positive reactions to quarterly updates but a sharp selloff on otherwise positive RESTORE-FA clinical data, indicating occasional divergence between fundamentals and price.
Over the last several months, Design Therapeutics has alternated between financial updates and clinical milestones. Q1 2026 results on Apr 28 highlighted $222.8M in cash and multiple upcoming readouts, with a strong 23.26% price gain. In contrast, the positive RESTORE-FA DT-216P2 data on May 18 coincided with a 25.54% decline. Prior conference participation and webcasts generally saw minor moves, suggesting today’s Jefferies appearance continues a pattern of routine investor outreach without major immediate price impact.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m. ET in New York.
A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com.The webcast will be archived for at least 30 days following each presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck, THRUST
renee@thrustsc.com
